Frontiers in HIV Pathogenesis, Therapy and Eradication
HIV发病机制、治疗和根除的前沿
基本信息
- 批准号:8260640
- 负责人:
- 金额:$ 2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-01-09 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcademiaAcquired Immunodeficiency SyndromeAddressAntiviral TherapyAreaArtsBiologyBiology of HIV InfectionBritish ColumbiaCanadaCellsCellular biologyCessation of lifeChronic HepatitisCollaborationsCommunicationCommunication ResearchDrug FormulationsDrug resistanceEducational workshopEnvironmentExposure toFosteringGene ExpressionHIVHIV-1Highly Active Antiretroviral TherapyIndustryInternationalJointsKnowledgeMaintenanceMentorsMethodologyOutcomePathogenesisPatientsPharmacologyPrivate SectorRequest for ApplicationsResearchResearch PersonnelScienceScientistStudy modelsTrainingViralViral hepatitisVirusabstractingclinical practicedrug developmentexperiencefrontierinhibitor/antagonistinterestlatent infectionmeetingsnovelpandemic diseaseresistant strainsymposiumvirus host interaction
项目摘要
DESCRIPTION:
This application requests support for a Keystone Symposia meeting entitled Frontiers in HIV Pathogenesis, Therapy and Eradication, organized by Alan N. Engelman, Eric O. Freed and John M. Coffin, which will be held in Whistler, British Columbia, Canada from March 26-31, 2012. AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology, and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors, and important virus-host interactions. Speakers selected from submitted abstracts will fill-out workshops on pharmacological approaches and the cell biology of HIV infection.
PUBLIC HEALTH RELEVANCE:
The 2012 Keystone Symposium on Frontiers in HIV Pathogenesis, Therapy and Eradication will address key issues related to the control of the global HIV/AIDS pandemic including potential eradication of persistent viral reservoir(s) from patients. Considering that UNAIDS estimated 1.8 million AIDS-related deaths in 2009, the meeting is both timely and highly significant. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis, which will share a keynote address and two plenary sessions with this meeting.
说明:
本申请请求支持由Alan N.Engelman、Eric O.Freed和John M.Coffin组织的题为《艾滋病毒发病、治疗和根除的前沿》的Keystone研讨会,该会议将于2012年3月26-31日在加拿大不列颠哥伦比亚省惠斯勒举行。艾滋病是无法治愈的,因为潜伏感染艾滋病毒的细胞抵抗抗病毒治疗。讨论根除艾滋病毒的主题是潜伏感染背后的生物学,以及研究潜伏期和刺激前病毒基因表达的药理学方法的模型。关于艾滋病毒发病、治疗和根除前沿的Keystone研讨会将为学术界和工业界在艾滋病毒发病机制、药理学和根除领域的一系列科学家自由交流思想和尖端成果创造一个环境。与病毒进入、复制和致病的细胞生物学会议同时举行的联合全体会议将突出共同感兴趣的主题,包括病毒进入和抑制的机制,并将显著增加跨学科互动的机会。来自艾滋病毒复制和抗药性领域的领导人将严格审查抗病毒治疗、新型抑制剂和重要的病毒-宿主相互作用的状态。从提交的摘要中选出的发言者将填写有关药理学方法和艾滋病毒感染的细胞生物学的研讨会。
公共卫生相关性:
2012年艾滋病毒发病、治疗和根除前沿的Keystone研讨会将讨论与控制全球艾滋病毒/艾滋病大流行有关的关键问题,包括可能从患者体内根除持久性病毒储存库(S)。考虑到艾滋病规划署估计2009年有180万人死于艾滋病,这次会议既及时又意义重大。同时召开的病毒进入、复制和致病的细胞生物学会议将大大增加跨学科互动的机会,该会议将与本次会议举行一次主旨演讲和两次全体会议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Wavell Aiken其他文献
James Wavell Aiken的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Wavell Aiken', 18)}}的其他基金
Type 2 Immunity: Initiation, Maintenance, Homeostasis and Pathology
2 型免疫:启动、维持、稳态和病理
- 批准号:
8399493 - 财政年份:2013
- 资助金额:
$ 2万 - 项目类别:
Emerging Topics in Immune System Plasticity: Cellular Networks, Metabolic Control
免疫系统可塑性的新兴主题:细胞网络、代谢控制
- 批准号:
8400276 - 财政年份:2013
- 资助金额:
$ 2万 - 项目类别:
NF-kappaB Signaling and Biology: From Bench to Bedside
NF-kappaB 信号传导和生物学:从实验室到临床
- 批准号:
8253117 - 财政年份:2012
- 资助金额:
$ 2万 - 项目类别:
相似海外基金
Conference: Rethinking how language background is described in academia and beyond
会议:重新思考学术界及其他领域如何描述语言背景
- 批准号:
2335912 - 财政年份:2024
- 资助金额:
$ 2万 - 项目类别:
Standard Grant
ADVANCE Catalyst: Virtual Observatory of Culture for Equity in Academia at the University of Puerto Rico Rio Piedras (VoCEA)
ADVANCE Catalyst:波多黎各 Rio Piedras 大学学术界平等文化虚拟观察站 (VoCEA)
- 批准号:
2214418 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Standard Grant
Comprehensive development strategy of modality-specific "intellectual property" and "cultivation" with an eye on "pharmaceutical affairs" in academia drug discovery
学术界新药研发着眼“药事”的模式“知识产权”与“培育”综合发展策略
- 批准号:
23K02551 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating Research Advancement for Investigators Underrepresented in Academia
加速学术界代表性不足的研究人员的研究进展
- 批准号:
10746315 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Planning: HBCU-UP: Strengthening Data Science Research Capacity and Education Programs through Academia-Industry Partnership
规划:HBCU-UP:通过学术界与工业界合作加强数据科学研究能力和教育计划
- 批准号:
2332161 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Standard Grant
From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer
从学术界到商界:针对 HPV 相关癌症的新型疗法的开发
- 批准号:
10813323 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Academics4Rail: Building a Community of Railway Scientific Researchers and Academia for ERJU and Enabling a Network of PhDs (Academia Teaming with Industry)
Academys4Rail:为二院建立铁路科研人员和学术界社区并启用博士网络(学术界与工业界合作)
- 批准号:
10102850 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
EU-Funded
Academics4Rail: Building a community of railway scientific researchers and academia for ERJU and enabling a network of PhDs (academia teaming with industry)
Academys4Rail:为ERJU建立铁路科研人员和学术界社区并建立博士网络(学术界与工业界合作)
- 批准号:
10087488 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
EU-Funded
Exploring the overall picture of industry-academia-government collaboration: A spectrum of knowledge transfer through formal and informal channels
探索产学官合作的整体图景:通过正式和非正式渠道进行的一系列知识转移
- 批准号:
22K01692 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Fostering Ethical Neurotechnology Academia-Industry Partnerships: A Stakeholder Engagement and Toolkit Development Project
促进道德神经技术学术界与工业界的伙伴关系:利益相关者参与和工具包开发项目
- 批准号:
10655632 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别: